



VOL. 65 ISSUE 2


MYASTHENIA GRAVIS ASSOCIATION NEWSLETTER

INSIDE THIS ISSUE

Page 01	Message from Allison
Page 02	Welcome Halle Walker
Page 03	Expanding Treatment Access: New FDA Approvals
Page 04	Your Voice, Your Power
Page 07	Beat the Heat
Page 08	Clinical Trials Updates
Page 10	Where is the MGA?
Page 12	Upcoming Events
Page 13	Membership Donations
Page 15	Find a Support Group

Welcome Halle

In April, the Myasthenia Gravis Association welcomed a vibrant new addition to our team—Halle Walker, our new Event Coordinator. With a deep passion for both event planning and meaningful, mission-driven work, Halle is already bringing a fresh energy to MGA's programs and celebrations. We're thrilled for our community to begin seeing—and benefiting from—her thoughtful approach to event coordination and community building. Learn more about Halle on page 2.



Beat the Heat: Understanding Seasonal Trends and Staying Cool When It Counts

A newly published study from Italy, ("Seasonal Variation in the Onset of Myasthenia Gravis" – Journal of Neuroimmunology, Volume 399, 578524) recently caught our attention — and it might help explain why some people with Myasthenia Gravis (MG) feel worse in the summer. The study, which used both hospital and community data, linked this rise in MG diagnoses with higher environmental temperatures. This adds to what many people with MG already know from personal experience — heat can make MG symptoms worse. Read more about the connection between heat and worsening symptoms, and tips on how to stay cool when it counts on page 7.



www.mgac.org

NATIONAL

scribble day

www.mgac.org

I've always liked to draw but hadn't for several years. Then a year and half ago, my husband and I moved to a retirement village due to my myasthenia gravis and husband's mild dementia. They offered drawing classes, and my interest has renewed. This is a self-portrait I made in the last couple weeks of me out west photographing scenery and animals.

-Dottie

SUBMISSIONS

Want to share your MG story or have a topic you would like to see covered? We have multiple ways for you to connect with the MG community! Email Allison at allisonfoss@mgac.org

FOLLOW US



@mga_heartland



@myastheniakc



<https://www.facebook.com/mgac>



<https://www.youtube.com/user/mgac>

A MESSAGE FROM ALLISON

A Childhood Memory, A Grown-Up Perspective

Do you ever see something and instantly feel transported back in time?

This dollhouse is an iconic memory of my childhood. It used to be housed on the 2nd floor Pediatric Neurology Department at the University of Iowa Hospitals and Clinics. While you don't exactly look forward to going to the doctor as a child, stopping and gawking at the dollhouse was tradition on all my appointments there as a child. I know I got less excited to stop and look at the dollhouse as I aged.

I can't tell you my excitement as I saw the dollhouse again a few weeks ago in its new location at the former Mercy Hospital in downtown Iowa City, IA. Memories came flooding back of long days waiting to see the doctor with highly awaited exits as we left appointments where we'd wander by the dollhouse to take a peek inside.

I suppose one thing that is so intriguing about a dollhouse is the instant dream of the good life and where you see yourself going. Setting up house essentially. Seeing the dollhouse in my adult life has brought me to reflecting so much about the vision we have with our lives. And leads me to thinking about so many of the people that we work alongside. They never envisioned their life upended by a rare autoimmune neuromuscular disease. They never envisioned a life with therapies, treatments, doctors appointments and debilitating symptoms.

We all have this perfect little vision of the future. Something straight out of a dollhouse and then life happens. Whatever is happening in your life, we want to be part of it. We look forward to connecting and working together even when it's not how you thought life would be.



With gratitude,

Allison K. Foss | Executive Director | allisonfoss@mgakc.org



MGA STAFF

Executive Director
Allison Foss

Community Program Coordinators

Kathryn Clemens
McKenna Fulton

Event Coordinator

Halle Walker

EXECUTIVE BOARD

President
Michael Eagan

Vice President

Brodie Beck

Secretary

Stephanie Hubers

Treasurer

Derek Haverkamp

BOARD MEMBERS

Keith Asaeli
Joe Bant
Megan Choate
Al Dimmitt
Lyndsey Fliehs
Stephanie Hubers
Graham Naasz, DDS
Mamatha Pasnoor, MD, FAAN
Ashley Steele, CMP
Tom Vansaghi, PhD

CONTACT

816-256-4100
info@mgakc.org

Welcome **HALLE WALKER** Event Coordinator

Welcome Halle Walker, MGA's New Event Coordinator

Bringing Passion, Purpose, and Planning Expertise to the MG Community

In April, the Myasthenia Gravis Association welcomed Halle Walker to the team as our new Event Coordinator! Halle brings a strong background in planning and a passion for building meaningful, mission-driven experiences—making her a perfect addition to MGA.

Halle is a proud graduate of Iowa State University's Event Management program, one of the only programs in the U.S. dedicated specifically to event planning. She joins fellow Cyclone and MGA Executive Director Allison in bringing that Iowa State pride to the office! Her career began in the wedding industry, where she coordinated events across Iowa, Georgia, and most recently, Kansas City. While those roles sharpened her organizational and creative skills, Halle realized she wanted to bring her talents into a space where she could make a deeper impact.

"I've always been passionate about health, wellness, and nonprofit work," she said. "I wanted to be part of something that truly helps people—and that's what drew me to MGA."

What stood out about MGA? "The mission, hands down," she shared. "The way this organization supports patients and families through education, resources, and compassion—that's the kind of work I want to be part of."

As Event Coordinator, Halle is excited to create inclusive and engaging events for individuals with MG and their support networks. She's already looking forward to MGA's Annual Meeting and Educational Seminar, which celebrates its 65th anniversary this year.

"It's such an important event—not just for learning, but for bringing people together," she said.

Though new to the role, Halle is full of ideas to make events even more meaningful. Her goal? "To be a trusted representative of the MG community and help every attendee feels supported and connected." We're thrilled to have Halle on board and can't wait for you to meet her at an upcoming event!



At Janssen, we are **relentlessly** focused, **actively** listening, and **expertly** helping to develop innovative solutions for those living with rare diseases, including generalized myasthenia gravis (gMG).



BRIDGING THE GAP:

EXPANDING TREATMENT ACCESS

FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis

On March 10, 2025, the FDA approved the expanded use of eculizumab (Soliris) for pediatric patients aged six years and older with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. This approval marks the first and only FDA-approved treatment available for children living with this rare and debilitating neuromuscular disease.

More information: www.solirisnmosd.com



New Self-Injection Option Expands Access for MG Treatment

The FDA has approved a prefilled syringe version of VYVGART® Hytrulo—a subcutaneous injection designed for at-home self-administration. This advancement empowers individuals with generalized myasthenia gravis (gMG) who are anti-AChR antibody positive to take a more active role in their treatment routine. The self-injection takes just 20 to 30 seconds and may reduce the need for frequent clinic visits.

More information: www.vyvgart.com/gmg/getting-started/about-subcutaneous-injections



FDA Approves Imaavy™ (Nipocalimab) for Generalized Myasthenia Gravis

On April 17, 2025, the FDA approved Imaavy™ (nipocalimab-aahu) for adults with generalized myasthenia gravis (gMG) who are AChR antibody positive. It is the first FcRn blocker approved for gMG with the option of every-other-week maintenance dosing. Approval was based on data from the Phase 3 Vivacity-MG study showing meaningful symptom improvement.

More information: <https://www.jnj.com/media-center/press-releases>



REGENERON

SCIENCE TO MEDICINE®

About Regeneron

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Regeneron accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human and bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases. Learn more at www.Regeneron.com.



YOUR VOICE, YOUR POWER

VALUE IN POLICY

**EveryLife Foundation
and Community Congress,
identifies top legislative
priorities for people with
rare diseases**



Living with myasthenia gravis (MG) means navigating more than just a medical diagnosis—it often involves financial, systemic, and access challenges too. That's why federal policy matters. Every year, the rare disease community, led by the EveryLife Foundation and Community Congress, identifies top legislative priorities aimed at improving access, treatment development, and affordability for people with rare diseases—including those with MG. Here are the key 2025 federal priorities that directly impact the MG community—and what you can do to help.

Key 2025 Federal Priorities that Directly Impact the MG Community

- Protect & Strengthen the Accelerated Approval Pathway
- Orphan Drug Tax Credit (Cameron's Law) & Rare Pediatric Disease PRV Program
- Expand Medicaid Coverage for Genetic/Genomic Testing
- HELP Copays Act (S.864)
- Access to Home Infusion Act

Protecting Access to Life-Changing Therapies

Policy: *Protect & Strengthen the Accelerated Approval Pathway*

This pathway allows the FDA to approve treatments faster using biomarkers (surrogate endpoints) while confirmatory trials are underway. Several MG treatments—especially for those with rare or refractory forms—have benefited from this route.

Why It Matters to MG: Faster approval means earlier access to new treatment options. We need to ensure insurers continue to cover these life-changing therapies.

How to Help: Urge your elected officials to oppose restrictions on coverage for treatments approved through this pathway.

Incentivizing Drug Development for Rare and Pediatric Populations

Policy: *Orphan Drug Tax Credit (Cameron's Law) & Rare Pediatric Disease PRV Program*

These programs provide tax credits and priority review vouchers to encourage companies to invest in treatments for rare diseases and children. With a growing pipeline of MG treatments, continued incentives are essential.

Why It Matters to MG: Ongoing innovation ensures that more therapies become available, especially for younger patients or underserved subtypes.

How to Help: Support the renewal of these programs and thank your representatives for backing rare disease innovation.

YOUR VOICE, YOUR POWER

VALUE IN POLICY

**EveryLife Foundation
and Community Congress,
identifies top legislative
priorities for people with
rare diseases**



Improving Access to Genetic Testing

Policy: *Expand Medicaid Coverage for Genetic/Genomic Testing*

Although MG isn't always genetic, accurate diagnosis and differential diagnosis often involve testing that many still can't afford—especially for pediatric or early-onset cases.

Why It Matters to MG: Earlier diagnosis avoids delays, misdiagnoses, and inappropriate treatments.

How to Help: Share your diagnostic journey and advocate for insurance and Medicaid coverage for testing.

Ensuring Fair Coverage for Medication Costs

Policy: *HELP Copays Act (S.864)*

This bill requires insurers to count copay assistance toward deductibles and out-of-pocket maximums.

Why It Matters to MG: Many MG patients rely on financial assistance to afford treatment. When insurers don't count that help, patients pay more and risk disruptions in care.

How to Help: Ask your representatives to support the HELP Copays Act—because every dollar counts.

Expanding At-Home Treatment Access

Policy: *Access to Home Infusion Act*

This would cover drugs that need to be infused at home by a qualified provider under Medicare—something MG patients receiving IVIG or other infusions could benefit from.

Why It Matters to MG: In-home options reduce travel and infection risk and are especially important for immunocompromised patients.

How to Help: Share how home treatment would improve your life or a loved one's and urge support for the Joe Fiandra Access to Home Infusion Act.

Ready to Use Your Voice?

Advocacy starts with one action. Here's how you can make a difference:



Contact Your Legislators – Share how policy decisions impact your care at www.house.gov and www.senate.gov.



Tell Your Story – Your experience matters. Consider submitting a personal story for advocacy campaigns or social media.



Join Our Advocacy Alerts – www.everylifefoundation.org/newsletter-signup/ to be notified when key votes or campaigns are underway.

Together, we can help ensure the voice of the MG community is not only heard—but valued in every decision.

Two targeted treatments for adults with **generalized myasthenia gravis (gMG)**

UCB is committed to making a difference for people living with gMG by providing two treatment options



Is it time to rethink your current gMG therapy?

For people with gMG, symptoms present themselves differently in each diagnosed individual. While most people have fluctuating muscle weakness and fatigue, these symptoms vary from person to person and can range from mild to severe.

UCB offers two treatments that target different aspects of immune function related to gMG and have different methods of administration.



Scan to explore two distinct treatments that allow you and your doctor to choose the gMG treatment that fits your needs.

UCB OFFERS TWO TREATMENTS THAT TARGET gMG DIFFERENTLY:

An FcRn blocker

Harmful antibodies that cause gMG may stay in your body longer because of FcRn (neonatal Fc receptor).

A C5 inhibitor

Harmful anti-AChR antibodies activate part of your immune system called "complement," which works to attack your muscle cells.

Targeted treatments. More options.

Ask your doctor how a targeted therapy may help you meet your gMG treatment goals.

Learn more at [UCBforGMG.com](https://www.ucbforGMG.com)



Inspired by **patients.**
Driven by **science.**



Seasonal Trends

BEAT THE HEAT

How Could it Affect Me?

Understanding Seasonal Trends and Staying Cool When It Counts

A newly published study from Italy, (“Seasonal Variation in the Onset of Myasthenia Gravis” – Journal of Neuroimmunology, Volume 399, 578524) recently caught our attention — and it might help explain why some people with Myasthenia Gravis (MG) feel worse in the summer.

What the Study Found:

Researchers looked at 316 people diagnosed with MG over 10 years and found something surprising: more new MG cases occurred during the summer months (June to August) than any other season. The study, which used both hospital and community data, linked this rise in MG diagnoses with higher environmental temperatures. This research adds to what many people with MG already know from personal experience — heat can make MG symptoms worse. While this study focused on the onset of the disease, it reinforces the idea that extreme temperatures may play a role in how MG shows up and how it affects the body.

Why Does Heat Matter?

Heat can affect the way nerve signals are transmitted to muscles, which is already disrupted in MG. When the body gets too warm, people with MG may notice more fatigue, increased muscle weakness, or even difficulty swallowing or speaking. Staying cool isn't just about comfort — it's about managing your symptoms effectively.



Tips from the Community: Staying Cool with MG

Here's how some members of our MG community beat the heat:

- Stay indoors during peak heat hours.
- Wear cooling gear, like vests, scarves, or wristbands filled with cooling gel or ice packs.
- Use fans or air conditioning when possible — small portable units can be lifesavers.
- Hydrate often, even if you don't feel thirsty.
- Plan errands early in the day, when it's cooler outside.
- Take cool showers or baths to bring your core temperature down quickly.
- Talk to your doctor if symptoms worsen in the heat — they may help you adjust your medication schedule during summer months.

As one individual with MG put it, “I've learned to treat summer like a challenge — and that means adjusting my plans and listening to my body more closely.”

Why This Matters:

Recognizing patterns like these helps researchers better understand MG and helps people with MG plan ahead. If you or someone you love notices symptom changes in summer, know that you're not alone, and that even small changes to your routine can make a big difference.

MG CLINICAL TRIAL UPDATES

University of Kansas Medical Center



Janssen PI: Dr. Farmakidis
ClinicalTrials.gov Identifier: NCT05265273

An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Nipocalimab in Children aged 2 to Less than 18 Years With Generalized Myasthenia Gravis

For more information contact: Samantha Colgan, scolgan@kumc.edu

DAS-MG PI: Dr. Dimachkie ClinicalTrials.gov Identifier: NCT04226170
A Phase II, Study to Evaluate the Safety and Tolerability of Pyridostigmine When Given with Ondansetron to Subjects with anti-AchR positive Myasthenia Gravis

For more information contact: Nora Khalifa, nkhalifa@kumc.edu

ALXN1720 – MG PI: Dr. Dimachkie ClinicalTrials.gov Identifier: NCTC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis.

For more information: Abby Davis, adavis54@kumc.edu

KATALYST MG PI: Dr. Pasnoor ClinicalTrials.gov Identifier: NCT06064695
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis

For more information for the KU trial location contact: Abby Davis, adavis54@kumc.edu

MOM-M281-011 PI: Dr. Farmakidis ClinicalTrials.gov Identifier: NCT04951622
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis.

For more information contact: Ali Russo, aciersdorff@kumc.edu

Cabaletta Bio PI: Dr. Dimachkie ClinicalTrials.gov Identifier: NCT06359041
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Generalized Myasthenia Gravi

For more information: Lillian Saavedra, lsaavedra2@kumc.edu

Cabaletta Bio PI: Dr. Dimachkie clinicaltrials.gov identifier: NCT05451212
A Phase 1, Open-label, Safety and Dose-finding Study of Autologous Muscle-specific Tyrosine Kinase Chimeric Autoantibody Receptor T Cells (MuSK-CAART) in Subjects With Anti-MuSK-antibody-positive Myasthenia Gravis.

For more information contact: Andrew Heim, aheim2@kumc.edu

MG CLINICAL TRIAL UPDATES

University of Kansas Medical Center

COUR Pharma – MG PI: Dr. Dimachkie
ClinicalTrials.gov Identifier: NCT06106672

A Phase 1b/2a Double Blind, Randomized, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-106 in Subjects Ages 18–75 with Generalized Myasthenia Gravis
Experimental: ALXN1720

For more information contact: Abby Davis, adavis54@kumc.edu



University of Missouri

NMD Pharma PI: University of Missouri- Columbia
ClinicalTrials.gov Identifier: NCT06414954

This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.

For more information contact: Kristina Kelly, kristina.kelly@health.missouri.edu

COUR Pharma – MG PI: University of Missouri- Columbia
ClinicalTrials.gov Identifier: NCT06106672
A Phase 1b/2a Double Blind, Randomized, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-106 in Subjects Ages 18–75 with Generalized Myasthenia Gravis
Experimental: ALXN1720

For more information contact: Kristina Kelly, kristina.kelly@health.missouri.edu



Newly LAUNCHED REGEN MED

THERAPEUTIC APHERESIS &
MULTISPECIALTY INFUSION CENTER

15300 Kanis Road, Little Rock, AR 72223

501.246.5703



Dr. Tina S. Ipe, MD, MPH

Partial List of Therapies Offered

Actemra	Renflexis
Avsola	Rituxan
Benlysta	Ruxience
Cimzia	Simponi Aria
Entyvio	Soliris
Inflectra	Stelara
IVIG	Tepezza
Krystexxa	Truxima
Ocrevus	Tysabri
Orencia	Vyepti
Remicade	Xolair

Our **physician-operated medical home** offers a convenient alternative to the hospital for plasmapheresis and IV medications. We aim to provide customized treatments in a caring, professional, and relaxed environment. We offer **flexible scheduling** and work with you as the patient, physician, healthcare professional, and insurance provider to provide the treatments. **We manage the whole process after the referral is provided to us.**

We provide **therapeutic apheresis (plasmapheresis)** that treats 187 medical indications, including Myasthenia Gravis, Alzheimer's, and other autoimmune disorders. We also offer **therapeutic intravenous (IV) infusions** for, but not limited to:

- Hydration and electrolyte management
- Iron deficiency management
- Multispecialty medications

Onsite amenities include free parking, handicap access, private bays, wifi, snacks, and beverages. For more information, visit our website at <https://www.regenmed.vip/infusion>



WHERE IN THE WORLD IS THE MGA?



2025 MDA Clinical & Scientific Conference

In March, Allison Attended and hosted a booth at the 2025 MDA Clinical & Scientific conference in Dallas, TX.



World Orphan Drug Congress

At the end of April, Kathryn attended the World Orphan Drug Congress in Boston, MA. It was an opportunity to learn and form new connections in the rare disease community.



Carrell Krusen - Texas Neurology Conference

Allison had the privilege of sharing parts of her medical journey alongside members of the University of Kansas Medical Center Neurology Team at the Carrell Krusen - Texas Neurology Conference.



American Academy of Neurology Conference

At the beginning of April, Allison attended and hosted a booth at the American Academy of Neurology Conference in San Diego.



Wichita State University Health Fair

In March, members of our Wichita Support Group participated in the Wichita State University Health Fair. They were able to talk to medical students as well as other participants about MG.





EXPLORE THE POSSIBILITIES

Ask your doctor about VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) and VYVGART (efgartigimod alfa-fcab)

VYVGART® Hytrulo
(efgartigimod alfa and
hyaluronidase-qvfc)
Subcutaneous Injection
180 mg/mL and 2000 U/mL vial

VYVGART®
(efgartigimod alfa-fcab)
Injection for Intravenous Use
400 mg/20 mL vial



**Scan the QR code or visit
[VYVGART.com](https://www.vyvgart.com) to learn more**

Questions? Call 1-833-VYVGART (1-833-898-4278)

VYVGART is a registered trademark of argenx.
VYVGART Hytrulo is a trademark of argenx.
For U.S. audiences only.
©2024 argenx US-VYV-24-00096 V1 03/2024

argenx 

See You There UPCOMING EVENTS

At the MGA

5K RUN/WALK & TOT TROT

Date: May 18, 2025

Time: 8:00am

Location: Town Center Plaza, Leawood, KS

We are gearing up for the 14th Annual MGA Triple Crown Showdown at Town Center Plaza in Leawood, KS on Sunday May 18, 2025 and hope you'll join us! Select to participate in the 5K, Mile Mosey, Tot Trot or Stuck in Your Stall (Virtual). All funds raised through the MGA Triple Crown Showdown benefit services for the Myasthenia Gravis Association

Registration is \$30 and free for individuals diagnosed with MG. Email info@mgakc.org for a VIP code to use at checkout!

Website: www.mga5k.com

Facebook: [@mga5k](https://www.facebook.com/mga5k)

Instagram: [@mga5k](https://www.instagram.com/mga5k)



Snowflake Saturday

JUNE AWARENESS EVENTS

Date: Saturday June 7, 2025

Time: 10:00am - 1:00pm

Locations: Des Moines, Iowa | Little Rock, Arkansas | Wichita, Kansas

We're excited to announce Snowflake Saturday, a new awareness event. This unique event will combine education, community, and fun to raise awareness for myasthenia gravis and support those affected.

- Vendor Tables: Sponsored by pharmaceutical companies and specialty pharmacies.
- Raffles & Merchandise: Raffle prizes and MGA merchandise will be available for purchase.
- Speaker/Program: An informative session featuring a guest speaker or program to educate and inspire attendees.

Snowflake Saturday will serve as a valuable opportunity to connect with the MG community, learn more about ongoing resources, and spread awareness. Stay tuned for dates, locations, and details—together, we'll make this a day to remember!

CROWN TOWN TRIVIA NIGHT

Date: August 1, 2025

Time: TBA

Location: GEHA Field at Arrowhead Stadium, Kansas City, MO

For the last seven years, the Iowa State Alumni of Kansas City has partnered with the MGA to present the annual Crown Town Trivia Night! One of our most popular events, the evening is filled with three rounds of exciting trivia surrounded by a live and silent auction.

Join us for a night like no other and discover opportunities on how to get involved! We are excited to return to GEHA Field at Arrowhead for the 7th Annual Crown Town Trivia Night.

More details coming soon via email!

Stay informed: www.mgakc.org



Membership Donations

Pamela Zurweller

Charlas Bales

Joe Bant

Derek Haverkamp

Ken and Lola Cook

Joanne Kohn

Patti and Bill Plummer

Colleen Benson

Sara Bass

Lyndsey Fliehs

Al Dimmitt

April Zobel

Shannon Harris

Cindy Disque

Marty Yadick

Ann Boid

In Memory of Marjorie Anderson

Susan Lauritsen

Suzie Quigley

Sean Hixson

Lisa Suntrup

Patricia Loehnig

Dan Glazier and Nancy Snow

In Memory of Beverly Morningstar

Emma Lyles

Inge Dudda

Kathleen and James Jengeleski

Richard and Linda Snurr

Harold Barnes

James and Michele Wade

Emily and Merle Dentler

Susan Pakari

In Memory of Beverly Morningstar

Delores Degreef

Jean Brake

In Memory of Betty Hucke

Richard and Ann Woody

In Memory of Vern Sargent

Lynne O'Connor

Lisa Huffaker



ASPIRING

We're imagining the future of healthcare for those living with difficult-to-treat conditions like infertility, multiple sclerosis and cancer.

Passion fuels us on our mission to transform lives.

#BeEMDSerono

EMD
SeRONO

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada © 2024 Merck KGaA, Darmstadt, Germany or its affiliates. All Rights Reserved. US-NONPR-00074.12/24

Shaping what's next, together

MG is complex and unpredictable. While each person's experience is unique, managing MG – even while on treatment – can be challenging.

A survey of 547 U.S. adults with MG showed that **more than 50% of respondents** reported a significant negative impact on their:



Energy



Physical activity



Ability to work

At Immunovant, we're committed to helping to address the complex and variable needs of people living with MG. Your voice drives our work as we pursue a patient-focused approach to researching therapies across disease stage and severity.

Tell us, what's your hope for what's next?

Share your perspective at:
tinyurl.com/yj2jkah3

Immunovant.com
Targeted science, tailored solutions



Source: 2022 MG in America Survey. Health Union.
©Immunovant, Inc. 2025



Find what makes you More Than MG

Join the community of patients, caregivers, and other advocates

Whether you're looking to hear more about MG, find a friend with the same diagnosis, or receive some motivation, there's a place for you in the More Than MG community.

Visit More Than MG to explore:

-  Patient stories shared through social media
-  Tips for living life beyond an MG diagnosis
-  Encouraging reminders and motivation
-  Resources for you and your loved ones



MoreThanMG.com 

Follow
@MoreThanMG



Use our More Than MG Instagram filter
to help spark awareness about vision impairment.



GO TO @MoreThanMG ON



INSTAGRAM TAP THE SPARKLES



ICON

SELECT THE "SEE MG" FILTER



Find A SUPPORT GROUP

Near you

Missouri

Eastsiders Lunch Bunch – Blue Springs

1st Wednesday of the month | 11:30 AM – 1:00 PM | Agape House 312 SW 19th Terrace Street, Blue Springs, MO
Light lunch provided | Open to individuals, caregivers & providers
Hosted by Carol Hunt & Raymond Hankins, Volunteer Support Group Leaders
Next Meetings – May 7, 2025, June 4, 2025, & August 6, 2025
RSVP to mckennafulton@mgakc.org

Kansas City Coffee Club

1st Thursday of the month | 9:30 AM – 10:30 AM | Location Varies
Coffee is Dutch treat | Open to individuals, caregivers & providers
Next Meeting – June 5, 2025
RSVP: info@mgakc.org

Greater Kansas City Support Group

Quarterly on a Saturday | 10:00 AM – 11:30 AM | St. Joseph Medical Center, Kansas City, MO
Light brunch is provided | Open to individuals, caregivers & providers
Next Meeting – July 12, 2025
RSVP: mckennafulton@mgakc.org

Kansas City Northland Support Group

January–September, bi-monthly on a Thursday | 12:00 PM – 1:30 PM | Primrose Retirement Community, 8559 N. Line Creek Road, Kansas City, MO
Light lunch is provided | Open to individuals, caregivers & providers
Hosted by Sandy Gardner, Volunteer Support Group Leader
Next Meeting – July 10, 2025
RSVP: mckennafulton@mgakc.org

Young Friends of the MGA – Kansas City

Quarterly at various locations in Kansas City | 6:00 PM – 8:00 PM
Open to individuals who are generally in their 20s, 30s and 40s
Next meeting – August 26, 2025 | TBA
RSVP: allisonfoss@mgakc.org



Find A **SUPPORT GROUP** Near you

Missouri

St. Joseph Support Group

Quarterly | 1:30 PM – 3:00 PM | Rolling Hills Library, 1912 N Belt Hwy St. Joseph, MO 64506

Open to individuals, caregivers & providers

Next Meeting – June 18, 2025

RSVP: donnasjmo@yahoo.com

Springfield Support Group

Quarterly on a Thursday | 5:30 PM – 7:00 PM | The Library Station, 2535 N Kansas Expy, Springfield, MO 65803

Open to individuals, caregivers & providers

Next Meeting – July 17, 2025

RSVP: mckennafulton@mgakc.org

Mid-Missouri Group

Quarterly on a Thursday | 5:30 PM – 7:00 PM | Daniel Boone Regional Library, 100 W. Broadway, Columbia, MO

Open to individuals, caregivers & providers

Hosted by Jonni Sutton, Volunteer Support Group Leader

Next Meeting – July 17, 2025

RSVP: kathrynclemens@mgakc.org

St. Louis Coffee Club

4th Thursday of the month | 10:30–11:30 AM | St. Louis Bread Company, 10221 Manchester Rd, Kirkwood, MO

Coffee is Dutch treat | Open to individuals, caregivers & providers

Next Meeting – May 22, 2025

RSVP: kathrynclemens@mgakc.org

St. Louis Support Group

Quarterly on a Saturday | 10:00 AM – 11:30 AM | Glendale City Hall Auditorium, St. Louis, MO

Light brunch provided | Open to individuals, caregivers & providers

Next Meeting – July 12, 2025

RSVP: kathrynclemens@mgakc.org

Young Friends of the MGA – St. Louis

Quarterly at various locations in St. Louis | 6:00 PM – 8:00 PM |

Open to individuals who are generally in their 20s, 30s and 40s

Next Meeting – September 18, 2025

RSVP: info@mgakc.org



Find A **SUPPORT GROUP** Near you

Iowa

Iowa Support Group

Bi-Monthly on the 2nd Wednesday | 7:00 PM – 8:00 PM | Kirkendall Public Library, 1250 SW District Dr, Ankeny IA
Open to individuals, caregivers & providers
Next Meeting – August 13, 2025
RSVP: info@mgakc.org

Kansas

Lawrence Support Group

Quarterly on a Thursday, rotates between Lawrence and Topeka, KS | 5:30 PM – 7:00 PM | Lawrence Public Library, 707 Vermont Street, Lawrence, KS
Open to individuals, caregivers & providers
Next Meeting – August 21, 2025
RSVP: mckennafulton@mgakc.org

Wichita Support Group

Quarterly on a Saturday | 11:00 AM – 1:00 PM | Wichita Public Library, Alford Branch 3447 S. Meridian St. Wichita, KS
Open to individuals, caregivers & providers
Hosted by Dana & Larry Paxson, Volunteer Support Group Leaders
Next Meeting – July 26, 2025
RSVP: info@mgakc.org

Arkansas

Central Arkansas Group

Quarterly on a Thursday | 5:30 PM – 7:00 PM | Regen Med, 15300 Kanis Road, Little Rock, AR
Open to individuals, caregivers & providers
Hosted by Griselda Torres & Kelsey Sims, Volunteer Support Group Leaders
Next Meeting – August 21, 2025
RSVP: kathrynclemens@mgakc.org

NW Arkansas Support Group

Quarterly Saturday | 10:00 AM – 11:30 AM | Springdale Public Library, 405 S. Pleasant St. Springdale, AR 72764
Open to individuals, caregivers & providers
Next Meeting – August 23, 2025
RSVP: kathrynclemens@mgakc.org



Find A **SUPPORT GROUP** Near you

Virtual

Muscle Makers

3rd Wednesday of the month | 2:00 PM – 3:00 PM | Via Zoom

A virtual community for individuals with MG to bring your hobbies to life. Bring your craft and creativity to your screen while connect with others.

Next Meeting – May 21, 2025

Register at mgakc.org

Virtual Monthly Meetup

4th Monday of the month |

6:30 PM – 7:30 PM | Via Zoom

Open to individuals, caregivers & providers

Next Meeting – May 27, 2025

Register at mgakc.org

MG Pride Group

Bi- Monthly on a Tuesday |

5:30 PM – 6:30 PM | Via Zoom

Open to individuals who identify as LGBTQ+ with MG, their allies and care partners

Hosted by Bryan Bosch, Volunteer Support Group Leader

Next Meeting – June 10, 2025

RSVP: info@mgakc.org

Young Friends of the MGA – Virtual Support Group

Quarterly via zoom |

6:00 PM – 7:00 PM | Via Zoom

Open to individuals who are generally in their 20s, 30s and 40s

Next Meeting – June 3, 2025

RSVP: info@mgakc.org



AMGEN

Amgen is proud to
support the Myasthenia
Gravis Association.

Myasthenia Gravis Association
2340 E. Meyer Blvd. Building 1, Suite
300A Kansas City, MO 64132
Phone: (816) 256-4100
Email: info@mgakc.org
www.mgakc.org

**Become a 2025 Member of the
MYASTHENIA GRAVIS
ASSOCIATION**

Cut and enclose in envelope. Mail to MGA address below.

I want to support the MGA by becoming a 2025	
Basic Member	\$25.00 ☐
65th Anniversary Member	\$64.00 ☐
Sustaining Member	\$100.00 ☐
Patron Member	\$500.00 ☐
Lifetime Member	\$1,000.00 ☐
In memory of: _____ \$	
In honor of: _____ \$	

Name: _____	Address: _____	City, State, Zip: _____	Phone: _____	Email: _____
I am a: ☐ MG PATIENT	☐ RELATIVE	☐ FRIEND	☐ OTHER	
-Contributions may be tax deductible				
-Make checks payable to:				
Myasthenia Gravis Association				

MGA
2340 E. Meyer Blvd, Bld. 1, Suite 300A
Kansas City, MO, 64132